InvestorsHub Logo
Followers 30
Posts 4126
Boards Moderated 0
Alias Born 07/25/2007

Re: DewDiligence post# 2765

Tuesday, 11/21/2023 12:40:59 AM

Tuesday, November 21, 2023 12:40:59 AM

Post# of 3011

• EDP-938 (RSV N-protein inhibitor): ENTA expects to report data from the phase-2b RSVPEDs (pediatric) and the phase-2b RSVHR (high-risk adults) trials in calendar 3Q23, assuming there is a normal RSV season in the Northern Hemisphere.

• EDP-323 (RSV L-protein inhibitor): ENTA just started a phase-2a “challenge” study; data expected in calendar 3Q23.



Dew, the data for both RSV drugs is expected in Q3 2024 not 2023.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News